NVO241108C146000
- 0.00
- 0.000.00%
Novo-Nordisk A/S Newsroom
10 Health Care Stocks Whale Activity In Today's Session
The weight-loss miracle drug Wegovy is gaining popularity! How should we view novo-nordisk a/s's performance?
The weight-loss miracle drug Wegovy is gaining popularity! How should we view novo-nordisk a/s's performance?
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,000 Today
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Hims & Hers Health (HIMS.US) will launch a generic version of the old weight loss therapy of novo-nordisk a/s (NVO.US).
Hims & Hers Health CEO Andrew Dudum stated that the company is preparing to launch a non-patented version of novo-nordisk a/s's old version GLP-1 weight loss therapy liraglutide in 2025.
Hims & Hers to Launch a Generic for Novo's Older GLP-1
Viking Therapeutics (VKTX.US) weight loss drug emerging unexpectedly, challenging the traditional leaders in the field.
The data released earlier on Monday by viking therapeutics on the weight-loss drug VK2735 indicates that novo-nordisk a/s and eli lilly and co, currently dominating the obesity drug market, may face fierce competition in the future.
Futu Morning Post | Countdown to the election! The panic index VIX is burning high and uncertainty is haunting the market nerves; Up nearly 13% after hours! Palantir raises full-year revenue guidance
Jpmorgan warns: If Trump wins on Wednesday, the Fed may pause the easing cycle as early as December; Will the US stock market hit new highs after the election? Jpmorgan: FOMO psychology boosts, S&P may hit 6100 points by the end of the year; US polls: Harris and Trump are neck and neck in key 'swing states'.
US stocks closed: Trump, Harris concept stocks rose together, Chinese concept stocks remained stable and rose.
1. The market is filled with a wait-and-see attitude, with all three major indexes collectively falling. 2. Trump's media technology group rebounded after hitting bottom. 3. Photovoltaic and clean energy concept stocks strengthened collectively. 4. Reports claim that Nvidia will distribute Super Micro Computer orders to other suppliers.
Viking Stock Drops 13% After Jumping 9% on Obesity Drug Data
New Study Reveals Another Benefit in Using Novo Nordisk's Wegovy in Obesity
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
Nvidia rises to the top again! Surpassing Apple to become the global market cap leader.
The global market cap leader changes hands again.
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
What's Going On With Hims & Hers Health Stock Monday?
Novo Holdings Planned $16.5B Planned Acquisitions of Catalent Gets EU Inquiry
New weight loss drug CagriSema planned to be launched by novo-nordisk a/s is expected to alleviate the problem of rebound after discontinuation, with a minimum weight loss of 25%!
CagriSema combines the two ingredients of semaglutide and pancreatic amylase, is expected to achieve the best efficacy in history with a 25% weight loss, compared to the previous generation of weight loss drug Wegovy, it will not bring additional side effects, and is expected to alleviate gastrointestinal side effects such as nausea and vomiting.
Novo Nordisk's Drug Prices and Production Capacity in Focus -- Earnings Preview
Novo Nordisk, Ascendis Partner to Advance Once-monthly Obesity Drug Candidate
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?